Increased somatic mutations and increased ALK-activating subclonal/clonal mutations have been reported in relapsed neuroblastomas compared to tumors at diagnosis; the frequency of these mutations is higher than 20% and rises as tumors and/or plasma from relapsed patients are sequenced more routinely (10, 16, 17). This evidence concerns the gene ALK and neuroblastoma.